Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2015-04-30
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Aerucin 2.0mg/kg
Aerucin 2.0mg/kg
IV Aerucin 2.0 mg/kg over 1 hour
Group 2
Aerucin 8.0mg/kg
Aerucin 8.0mg/kg
IV Aerucin 8.0 mg/kg over 1 hour
Group 3
Aerucin 20.0mg/kg
Aerucin 20.0 mg/kg
IV Aerucin 20 mg/kg over 1 hour
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aerucin 2.0mg/kg
IV Aerucin 2.0 mg/kg over 1 hour
Aerucin 8.0mg/kg
IV Aerucin 8.0 mg/kg over 1 hour
Aerucin 20.0 mg/kg
IV Aerucin 20 mg/kg over 1 hour
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Is male or female
3. Is age ≥18 years and ≤50 years
4. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
5. Agrees to avoid elective surgery for the duration of the study
6. For female subjects: agrees to have avoided pregnancy from 14 days prior to Study Day 0 through the duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include: a sterile sexual partner; sexual abstinence (not engaging in any sexual intercourse); hormonal contraceptives (oral, injection, transdermal patch, or implant); vaginal ring; intrauterine device (IUD); or condom.
7. Has general good health, confirmed by medical history and physical examination
8. Has body mass index (BMI) between 18 and 30 (weight/height) -
Exclusion Criteria
2. Abnormal CBC laboratory values (per local laboratory parameters) from blood collected at screening (\>5% above ULN or \>5% below LLN)
3. Abnormally elevated laboratory values (per local laboratory parameters) from blood collected at screening for ALT, AST, total bilirubin, alkaline phosphatase (ALP), blood urea nitrogen (BUN), creatinine (Cr), (\>10% above ULN)
4. Abnormal urinalysis that, in the opinion of the investigator, is clinically significant
5. Positive screening urine test for illicit drugs (opiates, cocaine, amphetamines)
6. Has received an immunoglobulin product in the 120 days prior to Study Day 0
7. History or evidence of autoimmune disease
8. History or evidence of any past, present, or future possible immunodeficiency state, including laboratory evidence of HIV 1 infection.
9. History or evidence of chronic hepatitis
10. History of evidence of Pseudomonas infection
11. Received a systemic antibiotic with 14 days prior to Study Day 0
12. Participation in any other investigational study during the study period
13. Received immunoglobulin or blood products within 90 days prior to Study Day 0
14. Received any investigational drug therapy or investigational drug within 60 days prior to Study Day 0
15. Received immunosuppressive medications other than inhaled or topical immunosuppressants within 45 days prior to Study Day 0
16. Inability to discontinue daily medications during the study other than: oral contraceptives, vitamins, nonprescription nutritional supplements, aspirin, antihistamines inhaled corticosteroids, inhaled beta agonists, inhaled anticholinergics
17. All female subjects: currently pregnant or lactating/nursing; positive screening urine pregnancy test; or positive urine pregnancy test on the day of any study dosing
18. History or evidence of allergic disease or reaction that, in the opinion of the investigator, may compromise the safety of the subject
19. History or evidence of any other acute or chronic disease that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the drug or compromise the safety of the subject
20. Medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol
21. Any other reason at discretion of the investigator -
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aridis Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammed Al-Ibrahim, MD
Role: PRINCIPAL_INVESTIGATOR
SNBL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SNBL-CPC
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ARC-11-01
Identifier Type: -
Identifier Source: org_study_id